Acarix Begins Trading on OTCQB, Expands Investor Base in the US

Acarix, a company specializing in medical devices for rapid assessment of coronary artery disease (CAD), has begun trading on the OTCQB Market in the United States under the ticker symbol ACIXF. This new listing complements its existing presence on the Nasdaq First North Growth Market in Stockholm.

According to Acarix CEO Aamir Mahmood, the United States represents the company's most important commercial market. The new listing is expected to allow a broader investor base to participate in Acarix's growth journey, potentially driving increased investment and expansion opportunities.

Acarix's flagship product, the CADScor System, is both CE-approved and FDA DeNovo-cleared. The device offers a non-invasive solution to help healthcare providers rule out CAD in patients experiencing chest pain. This can potentially reduce the need for costly and invasive diagnostic procedures.

Recently, a primary care clinic in the New Orleans metropolitan area placed a significant reorder of single-use patches for the CADScor System. These patches are essential for the system's operation in evaluating patients suspected of having coronary artery disease. Additionally, Acarix received a multi-order for the CADScor System from Saving Grace Concierge, which will use the device as a diagnostic aid for symptomatic patients in the Oklahoma City and Tulsa metro areas.

Looking ahead, Mahmood outlined the company's focus on top-line growth, reimbursement efforts with CMS and private payers, and initiating clinical trials. He emphasized the potential of the CADScor System to save significant healthcare costs and drive commercial success in the US market.

For more details, you can view the source version on newsdirect.com.